Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Spark Therapeutics, Inc.    ONCE

SPARK THERAPEUTICS, INC.

(ONCE)
SummaryQuotesNewsRatingsCalendarCompany 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Spark Therapeutics : Swiss drugmaker Roche again extends $4.3 billion Spark offer until December 16

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/09/2019 | 01:19am EST

Swiss drugmaker Roche again extended its offer for shares of gene therapy specialist Spark Therapeutics to Dec. 16 as a regulatory review of the $4.3 billion (3.35 billion pounds) transaction drags on.

All terms and conditions of Roche's offer remain unchanged, it said in a statement on Monday.

(Reporting by John Miller; editing by Thomas Seythal)

Stocks mentioned in the article
ChangeLast1st jan.
ROCHE HOLDING AG 2.18% 327.95 Delayed Quote.2.21%
SPARK THERAPEUTICS, INC. 0.00%End-of-day quote.0.00%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SPARK THERAPEUTICS, INC.
2019Trouble for Boeing, Netflix expands, Amazon toughens up against Fedex…
2019SPARK THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Compl..
AQ
2019SPARK THERAPEUTICS : Roche and Spark Therapeutics, Inc. announce closing of inve..
AQ
2019Roche to complete $4.3 billion Spark deal as regulators give all clear
RE
2019Roche to complete $4.3 billion Spark deal as regulators give all clear
RE
2019SPARK THERAPEUTICS : Roche clears UK hurdle in $4.3 billion Spark deal, U.S. rev..
RE
2019EUROPE : European shares dragged down by Tullow Oil and weak China export data
RE
2019ROCHE : Extends Tender Offer for Spark Therapeutics
DJ
2019SPARK THERAPEUTICS : Swiss drugmaker Roche again extends $4.3 billion Spark offe..
RE
2019SPARK THERAPEUTICS : Roche extends offer deadline for Spark Therapeutics again
RE
More news
Chart SPARK THERAPEUTICS, INC.
Duration : Period :
Spark Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
Stephen W. Webster Chief Financial & Accounting Officer
Federico Mingozzi Chief Scientific Officer
Bruce Resnick Director
Sean A. Johnston Director
Joseph W. La Barge Chief Legal Officer & General Counsel
Sector and Competitors
1st jan.Capitalization (M$)
SPARK THERAPEUTICS, INC.0.00%4 375
GILEAD SCIENCES-2.74%81 222
VERTEX PHARMACEUTICALS7.56%59 080
REGENERON PHARMACEUTICALS4.07%42 376
WUXI APPTEC CO., LTD.3.66%22 772
GENMAB2.36%14 701